Navidea Biopharmaceuticals, Inc. announced that it has entered into a Stock Purchase Agreement with two accredited investors pursuant to which the company agreed to issue a private placement a total of 11,000 shares of Series J convertible preferred stock at a price of $100 per share for the gross proceeds of $1,100,000 on May 22, 2023.The Company also agreed to provide the investors with certain registration rights related to the resale of the shares of the company's common stock, par value $0.001 per share issuable upon conversion of the Series J preferred stock.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0392 USD | -2.00% | +12.00% | -28.99% |
1st Jan change | Capi. | |
---|---|---|
-28.99% | 3.92M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- NAVB Stock
- News Navidea Biopharmaceuticals, Inc.
- Navidea Biopharmaceuticals, Inc. announced that it expects to receive $1.1 million in funding